Aristopharma Ltd



Aristopharma has launched Caspa 50 mg & 200 mg Tablet for the treatment of fungal infections

Caspa (Voriconazole) is a second generation triazole antifungal drug that inhibits fungal cell growth by interfering ergosterol biosynthesis. It is indicated for the treatment of invasive aspergillosis, candidemia, esophageal candidiasis and other serious fungal infections. Caspa (Voriconazole) has an enhanced spectrum of activity, greater efficacy, lower resistance and lower mortality rate in invasive fungal infections compared to other antifungal drugs.